Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
115.07
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arcellx Employees
Arcellx had 209 employees as of December 31, 2025. The number of employees increased by 46 or 28.22% compared to the previous year.
Employees
209
Change (1Y)
46
Growth (1Y)
28.22%
Revenue / Employee
$106,632
Profits / Employee
-$1,095,378
Market Cap
6.75B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ImmunityBio | 691 |
| Halozyme Therapeutics | 423 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 238 |
| Protagonist Therapeutics | 132 |
| Centessa Pharmaceuticals | 118 |
| Erasca | 103 |
ACLX News
- 11 hours ago - Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
- 5 weeks ago - Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 5 weeks ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 7 weeks ago - Top 2 Health Care Stocks That May Crash This Quarter - Benzinga
- 2 months ago - Here's Why Shares of Arcellx Are Up Almost 80% Today - Investopedia
- 2 months ago - Why is Arcellx stock up 80% today? Gilead's $7.8B answer - Invezz
- 2 months ago - Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - Reuters
- 2 months ago - Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion - WSJ